At the news
? NEUTRALIMPACT 4/10 DEFA14A filed Jul 10, 2026 at 06:02 ET
Outlook Therapeutics filed a DEFA14A supplement to its proxy statement, updating shareholders that it regained Nasdaq minimum bid price compliance as of June 25, 2026 after a prior delisting notice, but warning that the stock closed at only $1.68 on July 9 and remains vulnerable to re-listing risk if price falls below $1.00 again. The supplement emphasizes that the reverse stock split proposal remains relevant as a contingency against future non-compliance.
- Outlook Therapeutics received a Nasdaq delisting notice on February 18, 2026 for failing to maintain $1.00 minimum bid price
- On June 26, 2026, Nasdaq confirmed the company regained compliance as closing bid price was ≥ $1.00 for 10 consecutive business days (June 11–25, 2026)
- As of July 9, 2026, the closing price was $1.68 per share; the company warns it could decline below $1.00 again
- The board's reverse stock split authorization (Proposal No. 3) remains a contingency tool; if not implemented within one year of the meeting, further shareholder approval will be needed
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access